Claims for Patent: 10,155,932
✉ Email this page to a colleague
Summary for Patent: 10,155,932
| Title: | Decreasing potential iatrogenic risks associated with influenza vaccines |
| Abstract: | Influenza viruses for use in preparing human vaccines have traditionally been grown on embryonated hen eggs, although more modern techniques grow the virus in mammalian cell culture e.g. on Vero, MDCK or PER.C6 cell lines. The inventor has realised that the conditions used for influenza virus culture can increase the risk that pathogens other than influenza virus may grow in the cell lines and have identified specific contamination risks. Suitable tests can thus be performed during manufacture in order to ensure safety and avoid iatrogenic infections. |
| Inventor(s): | Gregersen Jens-Peter |
| Assignee: | Novartis AG |
| Application Number: | US15150214 |
| Patent Claims: |
Details for Patent 10,155,932
| Applicant | Tradename | Biologic Ingredient | Dosage Form | BLA | Approval Date | Patent No. | Expiredate |
|---|---|---|---|---|---|---|---|
| Glaxosmithkline Biologicals | FLUARIX, FLUARIX QUADRIVALENT | influenza vaccine | Injection | 125127 | August 31, 2005 | 10,155,932 | 2036-05-09 |
| Glaxosmithkline Biologicals | FLUARIX, FLUARIX QUADRIVALENT | influenza vaccine | Injection | 125127 | December 14, 2012 | 10,155,932 | 2036-05-09 |
| Id Biomedical Corporation Of Quebec | FLULAVAL, FLULAVAL QUADRIVALENT | influenza vaccine | Injection | 125163 | October 05, 2006 | 10,155,932 | 2036-05-09 |
| >Applicant | >Tradename | >Biologic Ingredient | >Dosage Form | >BLA | >Approval Date | >Patent No. | >Expiredate |
Showing 1 to 3 of 3 entries
